No effects of nirmatrelvir/ritonavir on darunavir plasma trough concentrations : a case report
© European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ..
COVID-19 may be associated with worst outcomes in people living with HIV compared with HIV-negative patients. Nirmatrelvir/ritonavir can be safely co-administered with all the HIV antiretroviral drugs, without considering dose adjustment. However, no studies have formally investigated the effect of a double booster (ritonavir plus cobicistat) regimen on darunavir concentrations. We presented a case describing the lack of effects of adding nirmatrelvir/ritonavir on darunavir plasma trough concentrations in a patient with HIV already on treatment with a booster-based antiretroviral regimen. We believe this could be a reassuring message for physicians, allowing them to prevent unnecessary denial of COVID-19 treatment or inappropriate discontinuation of co-medications in patients with HIV.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
European journal of hospital pharmacy : science and practice - (2024) vom: 10. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cattaneo, Dario [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COMMUNICABLE DISEASES |
|---|
| Anmerkungen: |
Date Revised 10.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1136/ejhpharm-2023-004015 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366903993 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366903993 | ||
| 003 | DE-627 | ||
| 005 | 20240114234013.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/ejhpharm-2023-004015 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1256.xml |
| 035 | |a (DE-627)NLM366903993 | ||
| 035 | |a (NLM)38199809 | ||
| 035 | |a (PII)ejhpharm-2023-004015 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cattaneo, Dario |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a No effects of nirmatrelvir/ritonavir on darunavir plasma trough concentrations |b a case report |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a COVID-19 may be associated with worst outcomes in people living with HIV compared with HIV-negative patients. Nirmatrelvir/ritonavir can be safely co-administered with all the HIV antiretroviral drugs, without considering dose adjustment. However, no studies have formally investigated the effect of a double booster (ritonavir plus cobicistat) regimen on darunavir concentrations. We presented a case describing the lack of effects of adding nirmatrelvir/ritonavir on darunavir plasma trough concentrations in a patient with HIV already on treatment with a booster-based antiretroviral regimen. We believe this could be a reassuring message for physicians, allowing them to prevent unnecessary denial of COVID-19 treatment or inappropriate discontinuation of co-medications in patients with HIV | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COMMUNICABLE DISEASES | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Clinical Competence | |
| 650 | 4 | |a DRUG INCOMPATIBILITY | |
| 650 | 4 | |a Drug Monitoring | |
| 700 | 1 | |a Pagano, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Lazzarin, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Calvagna, Nunziata |e verfasserin |4 aut | |
| 700 | 1 | |a Gervasoni, Cristina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of hospital pharmacy : science and practice |d 2012 |g (2024) vom: 10. Jan. |w (DE-627)NLM225772213 |x 2047-9956 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:10 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/ejhpharm-2023-004015 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 10 |c 01 | ||